Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first,
second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.